Observation on Clinical Effect of Xiaoqinglong Decoction combined with Western Medicine in Treating Phlegm-Dampness Lung Syndrome in Acute Exacerbation of COPD

Abstract

Abstract: Objective To observe the clinical effect of Xiaoqinglong Decoction combined with Western medicine in the treatment of phlegm-dampness lung syndrome of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 80 patients with AECOPD syndrome of phlegm-dampness and lung retention admitted to the Linyi Hospital of Traditional Chinese Medicine from January 2022 to December 2022 were selected and divided into two groups according to random number table method, 40 cases in each group. Both groups were treated with conventional treatment, and the observation group was treated with supplemented Xiaoqinglong decoction on the basis of conventional western medicine treatment. Calculate the clinical efficacy of two groups,the cough relief time, asthma disappearance time and wheezing noise disappearance time of the two groups were observed. Levels of serum tumor necrosis factor-α (TNF-α), peripheral blood interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and percentage of forced expiratory volume in the first second to forced vital capacity (FEV₁/FVC) before and after treatment. Results The cough relief time, asthma disappearance time and wheezing sound disappearance time in observation group were shorter than those in control group (P<0.05). After treatment, the serum levels of TNF-α, IL-6 and hs-CRP in the two groups were lower than before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the levels of FVC, FEV₁ and FEV₁/FVC in the two groups were improved compared with those before treatment, and the observation group was higher than the control group (P<0.05). The total effective rate of the observation group was significantly better than that of the control group (P<0.05). Conclusion Xiaoqinglong Decoction can inhibit the expression of inflammatory factors, reduce airway resistance, promote airway unobstruction, improve clinical symptoms and lung function, and improve clinical efficacy in treating AECOPD syndrome of phlegm dampness and lung accumulation.

Key words: acute exacerbation of COPD, phlegm-dampness lung syndrome, Xiaoqinglong decoction

CLC Number:

R256.14

NI Xun-qing, ZHANG Xin-wei, CHEN Xiang-jun, SONG Wen-cai, SHEN Qi-ming. Observation on Clinical Effect of Xiaoqinglong Decoction combined with Western Medicine in Treating Phlegm-Dampness Lung Syndrome in Acute Exacerbation of COPD[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(9): 7-12.

References

[1] VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary[J]. Am J Respir Crit Care Med,2017,195(5):557-582.
[2] WEDZICHA J A, SEEMUNGAL T A.COPD exacerbations: defining their cause and prevention[J]. Lancet,2007,370(9589):786-796.
[3] 中华医学会呼吸病学会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J].中国医学前沿杂志,2014,6(2):67-80.
[4] 慢性阻塞性肺疾病中西医结合管理专家共识写作组.慢性阻塞性肺疾病中西医结合管理专家共识(2023版)[J].中国全科医学,2023,26(35):4359-4371.
[5] 陈湘君. 中医内科学[M].上海:上海科学技术出版社,2001:15-41.
[6] 郑筱萸. 中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:54-58.
[7] 陈亚红. 2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志(电子版),2019,11(12):32-50.
[8] YIN P, WU J, WANG L, et al.The Burden of COPD in China and Its Provinces: Findings From the Global Burden of Disease Study 2019[J].Front Public Health,2022,10:859499.
[9] WANG C, XU J, YANG L, et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet,2018,391(10131):1706-1717.
[10] 贾高峰,李芳,田丽.高雅主任医师运用小青龙汤加减治疗外寒内饮型肺系疾病经验[J].中医研究. 2021,34(11):77-80.
[11] 段治钓. 胡希恕《金匮要略》学习笔记[M].2版.北京:中国中医药出版社,2017.
[12] 俞昌. 医门法律[M].北京:中国医药科技出版社,2019:253.
[13] 赵佶敕. 圣济总录[M].北京:中国中医药出版社,2018:1461.
[14] 张平安,高娜,陈明哲,等.基于网络药理学探讨小青龙汤治疗慢性阻塞性肺疾病的作用机制[J].世界中医药,2021,16(24):3585-3590,3595.
[15] 臧凝子,李品,庞立健,等.基于网络药理学和生物信息学筛选小青龙汤治疗支气管哮喘的关键基因和通路[J].中国实验方剂学杂志,2021,27(3):171-183.
[16] NAVARRO-NÚÑEZ L, LOZANO M L, MARTÍNEZ C, et al. Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases[J]. Fitoterapia,2010,81(2):75-80.
[17] 何依津,张鹏志,田海月,等.槲皮素通过MAPK/ERK1/2信号途径对H9C2细胞抗缺氧损伤的作用[J].第三军医大学学报,2021,43(20):2220-2225.
[18] 雷晓青,陈鳌,刘毅,等.山萘酚药理作用的研究进展[J].微量元素与健康研究,2017,34(2):61-62.
[19] 张迪,张冬梅,陆瑞敏,等.基于“肺主行水”理论探究小青龙汤调节肺水转运蛋白的作用机制[J].中国实验方剂学杂志,2022,28(8):1-11.
[20] 舒莉莉,谢进.小青龙汤加减对慢性支气管炎急性发作期T淋巴细胞亚群及临床意义[J].世界中医药,2020,15(13):1977-1980,1984.
[21] 符秀曼,张美萃,范良,等.基于NF-κB通路和COX-2水平探讨小青龙汤加减方对LPS联合香烟烟雾诱导的COPD小鼠气道炎症和气道重塑的影响[J].中药材,2021,44(11):2692-2696.
[22] CORNWELL W D, KIM V, SONG C, et al.Pathogenesis of inflammation and repair in advanced COPD[J]. Seminars in Respiratory and Critical Care Medicine,2010,31(3):257-266.
[23] Chang C, Guo Z, Shen N, et al.Dynamics of inflammation resolution and symptom recovery during AECOPD treatment[J]. Sci Rep,2015,4(1):5516.
[24] YANG D, WANG L, JIANG P, et al.Correlation between hs-CRP, IL-6, IL-10, ET-1, and Chronic Obstructive Pulmonary Disease Combined with Pulmonary Hypertension[J]. Journal of Healthcare Engineering,2022,2022:3247807.
[25] 周璇,杨万春,王勇生,等.慢性阻塞性肺疾病急性加重期患者血清PCT,hs-CRP,DD和FIB与肺功能和预后的关系研究[J].现代生物医学进展,2020,20(16):3168-3171,3137.
[26] DAWSON R E, JENKINS B J, SAAD M I.IL-6 family cytokines in respiratory health and disease[J]. Cytokine,2021,143:155520.
[27] NAKAMOTO K, WATANABE M, SADA M, et al.Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: A potential mechanism for progression and exacerbation of COPD[J]. Experimental Lung Research,2019,45(8):255-266.
[28] KUBYSHEVA N, BOLDINA M, ELISEEVA T, et al.Relationship of Serum Levels of IL-17, IL-18, TNF-α, and Lung Function Parameters in Patients with COPD, Asthma-COPD Overlap, and Bronchial Asthma[J].Mediators of inflammation,2020,2020:4652898.
[29] FINCH S, LASKA I F, ABO-LEYAH H, et al.Validation of the COPD Assessment Test (CAT) as an outcome measure in bronchiectasis[J]. Chest, 2020,157(4):815-823.
[30] KAKAVAS S, KOTSIOU O S, PERLIKOS F, et al.Pulmonary function testing in COPD: looking beyond the curtain of FEV1[J]. NPJ Primary Care Respiratory Medicine,2021,31(1):23.
[31] BIKOV A, LANGE P, ANDERSON J A, et al.FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease[J]. International Journal of Chronic Obstructive Pulmonary Disease,2020,15:1135-1142.
[32] STEGMANN G M, HAHN S, DUNCAN C J, et al.Estimation of forced vital capacity using speech acoustics in patients with ALS[J]. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,2021,22(sup1):14-21.
[33] BHATT S P, BALTE P P, SCHWARTZ J E, et al.Discriminative accuracy of FEV1: FVC thresholds for COPD-related hospitalization and mortality[J]. JAMA,2019,321(24):2438-2447.